In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Rose Sheet

Executive Summary

Jonca Bull, MD, appointed deputy director, FDA Office of Drug Evaluation V, responsible for OTCs. Bull will report to ODE V Director Robert DeLap, MD/PhD, effective July 30. Debra Bowen, MD, left the position early this year to join McNeil Consumer Healthcare as VP-clinical research (1"The Rose Sheet" Jan. 3, p. 13). Currently acting director of the Office of Women's Health, Bull previously worked in the Office of the Commissioner as a special assistant and medical advisor to the deputy commissioner for operations. She joined FDA in 1994

Related Content




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts